Prohibits a pharmacist from substituting any anti-epileptic drug for the prescribed anti-epileptic drug without notification of and the informed consent of the prescriber and patient or such patient's parent, guardian or spouse.
Summary
Bill A05562 seeks to amend the public health law and the education law by prohibiting pharmacists from substituting prescribed anti-epileptic drugs without prior notification and informed consent from both the prescribing physician and the patient, or the patient's parent, legal guardian, or spouse. The bill defines anti-epileptic drugs and outlines the conditions under which substitutions can occur, emphasizing the importance of patient awareness and consent in the treatment of epilepsy and seizure disorders.
Impact
If enacted, this bill would significantly impact the way anti-epileptic medications are dispensed in New York State. It would require pharmacists to ensure that any substitution of anti-epileptic drugs, whether between brand and generic or among different generics, is done only after obtaining explicit consent from the relevant parties. This change aims to enhance patient safety and ensure that patients are informed about their treatment options, potentially affecting pharmacy practices and patient care protocols.
Sentiment
The sentiment surrounding Bill A05562 appears to be supportive among advocates for patient rights and safety, particularly those concerned about the management of epilepsy. However, there may be some contention from pharmacists and pharmacy organizations who could view the additional consent requirements as burdensome and potentially limiting their ability to provide cost-effective alternatives to patients.
Contention
Notable points of contention may arise from pharmacy groups who argue that the bill could complicate the dispensing process and limit their ability to manage costs effectively for patients. Conversely, advocates for epilepsy patients may argue that the bill is necessary to protect patients from potentially harmful substitutions that could affect their treatment outcomes. The balance between patient safety and pharmacist flexibility is likely to be a key area of debate.
Prohibits a pharmacist from substituting any anti-epileptic drug for the prescribed anti-epileptic drug without notification of and the informed consent of the prescriber and patient or such patient's parent, guardian or spouse.
Requires certain NJ FamilyCare providers to provide information to, and obtain consent form from, parent or guardian of child that provider is prescribing antipsychotic drug.
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals".
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals."
Requires notification by a prescriber or pharmacist of the substitution of one generic drug product for another generic drug product; requires both oral and written notification.
Requires a doctor to obtain the informed consent of patients prior to prescribing psychiatric drugs notifying the patients of possible adverse effects of the drug.